Searched for
WEGOVY SALES
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparationWith wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such a...
- Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
- Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launchLilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...
- Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 monthsThe drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...
- Novo Nordisk's Wegovy, Mounjaro sales in India double on month in JulySales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, s...
- Novo Nordisk stock plunges 23% after cutting sales forecast and naming Mike Doustdar as new CEONVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...
- Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
- Indiamart working with Novo Nordisk to halt illegal Wegovy salesThe drugmaker's India legal team held discussions with Indiamart's top executives to develop a "framework" for regularly alerting the onlin...
Load More
